Plain-English translation of NCT07016724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called cadonilizumab, when combined with standard radiation and chemotherapy, can help treat advanced esophageal squamous cell cancer more effectively. Cadonilizumab is a type of immune therapy that works by helping your body's immune system fight cancer cells. The study will compare patients who receive this medication along with standard treatment to patients who receive standard treatment alone, with the goal of improving outcomes before surgery.
Esophageal cancer is common in China, and while immune therapies have shown promise, current treatments still leave many patients without a complete response. This trial aims to find a more effective combination approach by adding this medication to standard pre-surgery treatment to help more patients benefit.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two groups: one group receives the new immune medication along with radiation and chemotherapy before surgery, and the other group receives radiation and chemotherapy alone. Both groups will then have surgery to remove the cancer. You will attend regular medical visits for treatment and monitoring, with the exact schedule depending on which group you are in and how your body responds to treatment.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China